イベント・学会参加情報
日にち
Nov 4-6, 2024
Location
Stockholm, Sweden
Booth #102
BIO Europe
Flexible solutions for biotech companies at every value inflection point
Expertise for Every Modality in Early Development
Certara offers new, emerging and VC-backed biotech companies a modern and data driven approach to drug development. Starting with the end in mind, Certara’s cross functional experts will support your team to further your scientific insights, optimize resources, and de-risk your therapy development journey.
Expertise for every modality:
- Small molecules, Biologics (monoclonal antibodies, ADCs)
- Complex biologics (Bispecific Abs, siRNA, oligonucleotides)
- Cell and Gene Therapies, Vaccines, Drug-device combos and Devices
Certara Strategy Early Development Solutions
候補選定からフェーズ1まで、各段階における専門家のサポート
候補物質の選定からフェーズ1プログラムの成功へと移行する上での課題を克服するには、医薬品開発における豊富な経験と専門知識が必要です。医薬品開発には、その高コスト、長期にわたる期間、高い脱落率など、特有の課題があります。候補物質が初期開発の全期間を通じて最適なアプローチを維持することは極めて重要です。初期段階で成功を収めることは、資金調達と提携機会の確保につながり、その後の段階での継続的な成功の基盤となります。
Strategic Partnerships for Early Development Success
Are you spending too much time managing multiple consultants/vendors, telling them what to do, and hoping your timelines don’t slip? Certara offers a strategic partnership that streamlines your early development work, allowing you to focus on what matters most.
Certara’s solutions:
- A full team of cross-functional virtual drug developers
- Relationships with individual experts who become an integrated part of your team
- Strategic recommendations from a collaborative partner invested in your success
Certara played a key role in Biohaven’s approval of Nurtec, contributing to the company’s acquisition by Pfizer for almost $12B. Check out a video testimonial here.
Our comprehensive services have recently helped clients:
- Achieve an accelerate approval in pediatric oncology
- Avoid the costly expense of entering Phase 1 with a starting dose that was too low
- Reach significant milestones in development and regulatory approval
Additional Resources
